SG11202101526YA - Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof - Google Patents
Novel cyclic dinucleotide derivative and antibody-drug conjugate thereofInfo
- Publication number
- SG11202101526YA SG11202101526YA SG11202101526YA SG11202101526YA SG11202101526YA SG 11202101526Y A SG11202101526Y A SG 11202101526YA SG 11202101526Y A SG11202101526Y A SG 11202101526YA SG 11202101526Y A SG11202101526Y A SG 11202101526YA SG 11202101526Y A SG11202101526Y A SG 11202101526YA
- Authority
- SG
- Singapore
- Prior art keywords
- antibody
- drug conjugate
- cyclic dinucleotide
- novel cyclic
- dinucleotide derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018167369 | 2018-09-06 | ||
PCT/JP2019/035198 WO2020050406A1 (ja) | 2018-09-06 | 2019-09-06 | 新規環状ジヌクレオチド誘導体及びその抗体薬物コンジュゲート |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101526YA true SG11202101526YA (en) | 2021-03-30 |
Family
ID=69722459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101526YA SG11202101526YA (en) | 2018-09-06 | 2019-09-06 | Novel cyclic dinucleotide derivative and antibody-drug conjugate thereof |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220008549A1 (he) |
EP (1) | EP3848054A4 (he) |
JP (2) | JP7254818B2 (he) |
KR (3) | KR20230122685A (he) |
CN (1) | CN112714649A (he) |
AU (2) | AU2019337051B2 (he) |
BR (1) | BR112021003472A2 (he) |
CA (1) | CA3111397A1 (he) |
CO (1) | CO2021004032A2 (he) |
IL (1) | IL281247A (he) |
MX (1) | MX2021002107A (he) |
PH (1) | PH12021550442A1 (he) |
SG (1) | SG11202101526YA (he) |
TW (2) | TWI825170B (he) |
WO (1) | WO2020050406A1 (he) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2022009597A (es) * | 2020-03-06 | 2022-09-02 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo-farmaco que incluye derivado de dinucleotido ciclico novedoso. |
WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
KR20230061360A (ko) | 2020-09-02 | 2023-05-08 | 다이이찌 산쿄 가부시키가이샤 | 신규 엔도-β-N-아세틸글루코사미니다아제 |
TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體-免疫賦活化劑共軛物之新穎製造方法 |
CN116917341A (zh) | 2021-03-12 | 2023-10-20 | 第一三共株式会社 | 糖链以及包含糖链的医药品的制造方法 |
US11806405B1 (en) | 2021-07-19 | 2023-11-07 | Zeno Management, Inc. | Immunoconjugates and methods |
CN115703845A (zh) * | 2021-08-05 | 2023-02-17 | 中国科学院上海药物研究所 | 寡糖连接子与侧链亲水性片段组合的糖链定点抗体-药物偶联物,其制法及用途 |
CN115957338A (zh) * | 2021-10-12 | 2023-04-14 | 成都科岭源医药技术有限公司 | 一种高稳定性的靶向接头-药物偶联物 |
CA3236388A1 (en) | 2021-10-29 | 2023-05-04 | Daiichi Sankyo Company, Limited | Novel oligosaccharide, manufacturing intermediate for novel oligosaccharide, and method for manufacturing these |
AU2022401024A1 (en) | 2021-11-30 | 2024-05-16 | Daiichi Sankyo Company, Limited | Protease-cleavable masked antibodies |
WO2024024935A1 (ja) * | 2022-07-29 | 2024-02-01 | 第一三共株式会社 | 抗腫瘍効果を有する抗体薬物複合体の新規製造方法 |
WO2024048490A1 (ja) * | 2022-08-29 | 2024-03-07 | 第一三共株式会社 | 変異Fc領域を含む抗体薬物コンジュゲート |
WO2024107827A1 (en) * | 2022-11-16 | 2024-05-23 | The Broad Institute, Inc. | Therapeutic exploitation of sting channel activity |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
EP0714409A1 (en) | 1993-06-16 | 1996-06-05 | Celltech Therapeutics Limited | Antibodies |
MXPA04004184A (es) | 2001-11-01 | 2005-01-25 | Uab Research Foundation | Combinaciones de anticuerpos selectivos para un receptor de ligando que induce apoptosis relacionada al factor de necrosis tumoral y otros agentes terapeuticos. |
PL214010B1 (pl) | 2002-07-15 | 2013-06-28 | Genentech Inc | Rekombinowane humanizowane przeciwcialo 2C4 i zastosowanie tego przeciwciala |
WO2004073656A2 (en) | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
MY150621A (en) | 2007-08-30 | 2014-02-14 | Daiichi Sankyo Co Ltd | Anti-epha2 antibody |
JP5566226B2 (ja) | 2009-09-03 | 2014-08-06 | 旭化成株式会社 | 11糖シアリルオリゴ糖ペプチドの製造方法 |
WO2014057687A1 (ja) | 2012-10-11 | 2014-04-17 | 第一三共株式会社 | 抗体-薬物コンジュゲート |
EP2931738B1 (en) | 2012-12-13 | 2019-02-06 | Aduro Biotech, Inc. | Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use |
AU2013363087B2 (en) | 2012-12-19 | 2018-07-19 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
SG11201508165VA (en) | 2013-04-29 | 2015-11-27 | Sloan Kettering Inst Cancer | Compositions and methods for altering second messenger signaling |
CN105188373B (zh) | 2013-05-18 | 2017-09-22 | 艾杜罗生物科技公司 | 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法 |
MX354057B (es) | 2013-05-18 | 2018-02-09 | The Regents Of The Univ Of California Star | Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón". |
WO2015074145A1 (en) | 2013-11-22 | 2015-05-28 | Brock University | Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants |
US10450341B2 (en) | 2014-06-04 | 2019-10-22 | Glaxosmithkline Intellectual Property Development Limited | Cyclic di-nucleotides as modulators of STING |
DE102014214408A1 (de) | 2014-07-23 | 2016-01-28 | Wacker Chemie Ag | Härtbare Organopolysiloxanzusammensetzungen |
WO2016096714A1 (en) | 2014-12-15 | 2016-06-23 | Henkel Ag & Co. Kgaa | Detergent composition comprising subtilase variants |
US11559581B2 (en) | 2015-01-09 | 2023-01-24 | Oxford University Innovation Limited | Antibody conjugates and methods of making the antibody conjugates |
MY190404A (en) | 2015-03-10 | 2022-04-21 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
IL290959B2 (he) * | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | תכשירים המכילים תצמידי נוגדן–תרופה ושיטות לייצורם |
EP3334745B1 (en) | 2015-08-13 | 2024-05-15 | Merck Sharp & Dohme LLC | Cyclic di-nucleotide compounds as sting agonists |
EP3368072A4 (en) | 2015-10-28 | 2019-07-03 | Aduro BioTech, Inc. | COMPOSITIONS AND METHOD FOR ACTIVATING SIGNALING DEPENDENT ON THE STIMULATOR OF THE INTERFERON GENE |
MA44334A (fr) * | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
CN107849084B (zh) | 2015-12-03 | 2021-09-14 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为sting调节剂的环状嘌呤二核苷酸 |
WO2017100305A2 (en) | 2015-12-07 | 2017-06-15 | Opi Vi - Ip Holdco Llc | Composition of antibody construct-agonist conjugates and methods of use thereof |
KR20180097751A (ko) | 2016-01-11 | 2018-08-31 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드 |
KR102530488B1 (ko) | 2016-03-18 | 2023-05-08 | 이뮨 센서, 엘엘씨 | 사이클릭 디-뉴클레오티드 화합물 및 사용 방법 |
KR20180132783A (ko) | 2016-04-07 | 2018-12-12 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 단백질 조절제로서 유용한 헤테로사이클릭 아미드 |
KR102527784B1 (ko) | 2016-04-07 | 2023-04-28 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 단백질 조정제로서 유용한 헤테로시클릭 아미드 |
KR102493562B1 (ko) | 2016-07-01 | 2023-01-30 | 다이이찌 산쿄 가부시키가이샤 | hANP-Fc 함유 분자 콘주게이트 |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
MX2019000216A (es) | 2016-07-06 | 2019-11-12 | Sperovie Biosciences Inc | Compuestos, composiciones y metodos para el tratamiento de enfermedades. |
WO2018045204A1 (en) | 2016-08-31 | 2018-03-08 | Ifm Therapeutics, Inc | Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity |
US10537590B2 (en) | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
CR20190168A (es) | 2016-10-04 | 2019-05-17 | Merck Sharp & Dohme | Compuestos de benzo[b]tiofeno como agonistas de sting |
WO2018065360A1 (de) | 2016-10-07 | 2018-04-12 | Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh | Benzimidazolhaltige cyclische dinukleotide, verfahren zu deren herstellung und ihre verwendung zur aktivierung von stimulator von interferongenen (sting)-abhängigen signalwegen |
JPWO2018066626A1 (ja) * | 2016-10-07 | 2019-07-18 | 第一三共株式会社 | 抗her2抗体−薬物コンジュゲート投与による耐性癌の治療 |
JOP20170192A1 (ar) * | 2016-12-01 | 2019-01-30 | Takeda Pharmaceuticals Co | داي نوكليوتيد حلقي |
JP2018090562A (ja) * | 2016-12-01 | 2018-06-14 | 武田薬品工業株式会社 | 環状ジヌクレオチド |
WO2018140831A2 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
TW202330036A (zh) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
-
2019
- 2019-09-06 CN CN201980058151.3A patent/CN112714649A/zh active Pending
- 2019-09-06 KR KR1020237027378A patent/KR20230122685A/ko not_active Application Discontinuation
- 2019-09-06 BR BR112021003472-2A patent/BR112021003472A2/pt unknown
- 2019-09-06 WO PCT/JP2019/035198 patent/WO2020050406A1/ja active Application Filing
- 2019-09-06 EP EP19857433.7A patent/EP3848054A4/en active Pending
- 2019-09-06 KR KR1020237005621A patent/KR102567591B1/ko active IP Right Grant
- 2019-09-06 JP JP2020541321A patent/JP7254818B2/ja active Active
- 2019-09-06 CA CA3111397A patent/CA3111397A1/en active Pending
- 2019-09-06 TW TW108132368A patent/TWI825170B/zh active
- 2019-09-06 US US17/273,666 patent/US20220008549A1/en active Pending
- 2019-09-06 TW TW112114344A patent/TW202330043A/zh unknown
- 2019-09-06 AU AU2019337051A patent/AU2019337051B2/en active Active
- 2019-09-06 SG SG11202101526YA patent/SG11202101526YA/en unknown
- 2019-09-06 MX MX2021002107A patent/MX2021002107A/es unknown
- 2019-09-06 KR KR1020217009642A patent/KR102567590B1/ko active IP Right Grant
-
2021
- 2021-03-02 PH PH12021550442A patent/PH12021550442A1/en unknown
- 2021-03-03 IL IL281247A patent/IL281247A/he unknown
- 2021-03-30 CO CONC2021/0004032A patent/CO2021004032A2/es unknown
-
2023
- 2023-02-27 AU AU2023201159A patent/AU2023201159A1/en active Pending
- 2023-03-28 JP JP2023050936A patent/JP7483975B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
CO2021004032A2 (es) | 2021-04-30 |
AU2023201159A1 (en) | 2023-03-30 |
JP2023073344A (ja) | 2023-05-25 |
KR102567590B1 (ko) | 2023-08-17 |
KR20230122685A (ko) | 2023-08-22 |
US20220008549A1 (en) | 2022-01-13 |
CN112714649A (zh) | 2021-04-27 |
IL281247A (he) | 2021-04-29 |
WO2020050406A1 (ja) | 2020-03-12 |
KR102567591B1 (ko) | 2023-08-16 |
JP7483975B2 (ja) | 2024-05-15 |
PH12021550442A1 (en) | 2021-11-22 |
KR20210057066A (ko) | 2021-05-20 |
EP3848054A1 (en) | 2021-07-14 |
AU2019337051B2 (en) | 2023-11-23 |
EP3848054A4 (en) | 2022-06-01 |
AU2019337051A1 (en) | 2021-04-29 |
TW202330043A (zh) | 2023-08-01 |
JPWO2020050406A1 (ja) | 2021-08-30 |
JP7254818B2 (ja) | 2023-04-10 |
TW202023628A (zh) | 2020-07-01 |
BR112021003472A2 (pt) | 2021-05-18 |
KR20230028589A (ko) | 2023-02-28 |
CA3111397A1 (en) | 2020-03-12 |
MX2021002107A (es) | 2021-04-28 |
TWI825170B (zh) | 2023-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL281247A (he) | נגזרות חדשות של דינוקליאוטידים ציקליים ותצמידי נוגדן-תרופה שלהן | |
IL291337A (he) | נגזרת קמפטותצין והצימוד שלה | |
IL284274A (he) | קוניוגטים של נוגדן ותרופה לשיפור חלון תרפויטי | |
SG11202101719PA (en) | Antibody-drug conjugate and application thereof | |
EP3626825A4 (en) | ANTI-CDH6 ANTIBODY AND ANTI-CDH6 ANTIBODY CONJUGATE-DRUG | |
EP3473270A4 (en) | ANTIBODY DRUG CONJUGATE | |
IL268102A (he) | נוגדן אנטי-gpr 20 ותצמיד תרופה-נוגדן אנטי-gpr 20 | |
IL272721A (he) | תכשיר תצמיד נוגדן-תרופה ושיטת ליופיליזציה | |
LT3794042T (lt) | Antikūno bei vaisto anti-muc1 ir eksatekano konjugatas | |
MX2021010550A (es) | Conjugados de anticuerpo-farmaco hidrofilicos. | |
EP3501548A4 (en) | ANTIBODY-ACTIVE SUBSTANCE CONJUGATE TISSUE FABRIC FACTOR | |
IL287391A (he) | אמטוקסין נוגדן–סמים כחומר מוצמד והשימוש בו | |
EP3412315A4 (en) | ANTI-HER2 ANTIBODY ACTIVE CONJUGATE AND ITS USE | |
EP3838893A4 (en) | LINKER, ANTIBODY-DRUG CONJUGATE COMPRISING THEM AND USE THEREOF | |
EP4043034A4 (en) | LYSOSOME TARGETING ANTIBODY-DRUG CONJUGATE AND USE THEREOF | |
IL284007A (he) | אנלוגים של ריפאמיצין ומצומדי נוגדן-תרופה שלהם | |
IL286847A (he) | מצמדים שקושרים hsp90 ופורמולציות שלהם | |
EP3599249A4 (en) | ANTI-5T4-DRUG ANTIBODY CONJUGATE AND ITS USE | |
IL277791A (he) | מצומדים מייעדים hsp90 ופורמולציות שלהם | |
IL283787A (he) | תצמידי נוגדן-תרופה הרבוקסידיאן ושיטות שימוש | |
IL265838A (he) | תצמיד של נוגדן עם תרופה המותאם על ידי ציסטאין ושיטה להכנתו | |
FI3666787T3 (fi) | Hemiasterliinijohdannaisen sisältäviä vasta-aine-lääkekonjugaatteja | |
EP3620471A4 (en) | ANTIBODY-ANTI-FIBRIN DRUG CONJUGATE INSOLUBLE, POSSIBLE TO BE CLIVID BY PLASMINE | |
IL291312A (he) | זיווגים נוגדן-תרופה נוגדי-ptcra ושימושם | |
EP3666788A4 (en) | HEMIASTERLIN DERIVATIVES AND ANTIBODY-ACTIVE INGREDIENT CONJUGATES CONTAINING THESE |